TMEM183A

Across TCGA pan-cancer cohorts, TMEM183A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of TMEM183A’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TMEM183A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM183A is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, THCA, and HNSC are the cancer types where TMEM183A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM183A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+1.163	<.001	9	view →
THCA	All	All	−0.270	<.001	9	view →
HNSC	All	III,IV	+0.538	<.001	8	view →
KICH	Female	All	−1.360	<.001	7	view →
BRCA	All	III,IV	+0.771	<.001	6	view →
LUSC	Male	All	+0.672	<.001	6	view →
UCEC	All	All	+0.462	.005	6	view →
BLCA	Female	All	+0.456	.001	6	view →
CHOL	All	II,III,IV	+3.024	<.001	5	view →
LUAD	Male	II,III,IV	+0.568	<.001	5	view →
STAD	All	II,III,IV	+0.398	.002	4	view →
KIRP	Female	II,III,IV	+0.688	.036	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

TMEM183A–LIHC

Open the LIHC breakdown →